State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation, XNA Platform, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China.
Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou 450052, China.
Int Immunopharmacol. 2024 Apr 20;131:111896. doi: 10.1016/j.intimp.2024.111896. Epub 2024 Mar 22.
CD155 is an immunoglobulin-like protein overexpressed in almost all the tumor cells, which not only promotes proliferation, adhesion, invasion, and migration of tumor cells, but also regulates immune responses by interacting with TIGIT, CD226 or CD96 receptors expressed on several immune cells, thereby modulating the functionality of these cellular subsets. As a novel immune checkpoint, the inhibition of CD155/TIGIT, either as a standalone treatment or in conjunction with other immune checkpoint inhibitors, has demonstrated efficacy in managing advanced solid malignancies. In this review, we summarize the intricate relationship between on tumor surface CD155 and its receptors, with further discussion on how they regulate the occurrence of tumor immune escape. In addition, novel therapeutic strategies and clinical trials targeting CD155 and its receptors are summarized, providing a strong rationale and way forward for the development of next-generation immunotherapies.
CD155 是一种免疫球蛋白样蛋白，几乎在所有肿瘤细胞中过度表达，它不仅促进肿瘤细胞的增殖、黏附、侵袭和迁移，还通过与几种免疫细胞上表达的 TIGIT、CD226 或 CD96 受体相互作用来调节免疫反应，从而调节这些细胞亚群的功能。作为一种新型免疫检查点，CD155/TIGIT 的抑制作用，无论是作为单一疗法还是与其他免疫检查点抑制剂联合使用，都已证明在治疗晚期实体恶性肿瘤方面具有疗效。在这篇综述中，我们总结了肿瘤表面 CD155 与其受体之间的复杂关系，并进一步讨论了它们如何调节肿瘤免疫逃逸的发生。此外，还总结了针对 CD155 及其受体的新型治疗策略和临床试验，为开发下一代免疫疗法提供了强有力的理由和前进方向。
